RayKnowChina Research Map
Shortlist0

RecruitingHaemophagocytic lymphohistiocytosisPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

Prospective Single-Arm Clinical Trial of GO Regimen for HLH.

An open trial on haemophagocytic lymphohistiocytosis, registered on ClinicalTrials.gov. Led by Beijing Friendship Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07339345, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 14 years to 70 years; sex: all

    Registered eligibility fields

  2. Women of childbearing age must be confirmed as not pregnant by a pregnancy test and must be willing to use effective contraception during the study period and for at least 12 months after the last dose; all male participants must use contraception during the study period and for at least 3 months after the last dose.

    Inclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07339345, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Researchers evaluate patients with newly diagnosed or refractory/relapsed HLH disease.
  • Definite diagnosis of HLH: molecular diagnosis consistent with pHLH, or at least 5 of the 8 criteria in the HLH-2004 diagnostic criteria.
  • Patients who are currently unsuitable or unable to undergo allo-HSCT.
  • Researchers estimate that the expected survival period exceeds one month.
  • Patients must be at least 14 years of age and no older than 70 years of age, with no gender restrictions.
  • Before the study began, TB was ≤10 times the upper limit of normal; Cr was ≤1.5 times the normal value.
  • Serum HIV antigen or antibody negative。
  • HCV antibody negative, or HCV antibody positive but HCV RNA negative.
  • .HBsAg and HBcAb are both negative. If either of the above is positive, peripheral blood hepatitis B virus DNA titer testing is required, with a titer of less than 1×10³ copies/ml.
  • Echocardiography showed LVEF ≥ 50%.
  • Women of childbearing age must be confirmed as not pregnant by a pregnancy test and must be willing to use effective contraception during the study period and for at least 12 months after the last dose; all male participants must use contraception during the study period and for at least 3 months after the last dose.

Exclusion Criteria:

  • Heart function above grade II(including II) (NYHA).
  • Pregnancy or lactating Women and reproductive-age patients who refused to use appropriate contraceptive measures during this trial.
  • Individuals who are allergic to GO or have a severe allergic constitution.
  • Active bleeding of the internal organs.
  • uncontrollable infection.
  • Severe mental illness.
  • History of non-melanoma skin cancer.
  • Unable to comply during the trial and/or follow-up phase. Participate in other clinical research at the same time.

Quoted from ClinicalTrials.gov, NCT07339345, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07339345, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07339345